Davion Healthcare PLC Agrees $13.5 Million Acquisition of Profitable US Home Healthcare Business
The proposed acquisition combines $8 million in cash with $5.5 million in Davion shares valued at $13 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Davion Healthcare (DAVI) has agreed to acquire Healthcare Stat Homecare, a Philadelphia-based home healthcare provider, for $13.5 million. The agreement, dated 27 October 2026, provides for $8 million in cash and $5.5 million in Davion shares valued at $13 per share. Completion is expected on or before 31 December 2026, subject to the acquisition agreement's terms.
For the year ended 31 December 2025, HSH reported unaudited gross receipts of approximately $11.6 million and ordinary business income of approximately $1.9 million. Davion expects the acquisition to add revenue and earnings after completion and extend its activities into home-based care. The company plans further acquisitions of established, revenue-generating and profitable healthcare businesses over the coming year to complement its healthcare technologies and diversify its operations.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.The $13.5 million acquisition agreement would extend Davion into home healthcare services. 16% of market cap
- Moderate pointHSH brings approximately $11.6 million gross receipts and $1.9 million ordinary business income for 2025, both unaudited.
- Minor point. Forward-looking: it has not happened yet and may not happen.Davion plans further acquisitions over the coming year of established, revenue-generating and profitable healthcare businesses.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.The acquisition requires $8 million in cash consideration from Davion. 9.7% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.$5.5 million in Davion shares at $13 per share would dilute existing shareholders.
- Minor pointCompletion remains pending, expected on or before 31 December 2026, subject to the acquisition agreement's terms.
Details
Market move: DAVI -5.47% vs previous close. home healthcare acquisition
On Oct 29, the day this news came out, the latest delayed price for DAVI is 5.47% below the previous close. Argus tracked a peak move of +9.3% during the session. Our momentum scanner has recorded 23 alerts for this stock so far that day. The latest delayed price is $3.11. Relative volume is exceptionally heavy at 53.6x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Total consideration
- $13.5 million
- Acquisition of HSH
- Cash consideration
- $8 million
- Acquisition payment
- Share consideration
- $5.5 million at $13 per share
- Shares issued at an agreed value
- Expected completion
- On or before December 31, 2026
- Subject to the acquisition agreement
AI-generated analysis. How Rhea-AI works. Not financial advice.
First in a planned programme of acquisitions to expand Davion’s revenues, earnings and healthcare operations
DUBLIN, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “Group”), a developer of non-invasive health monitoring technologies, announces that it has entered into an agreement dated 27 October 2026 to acquire Healthcare Stat Homecare Inc. (“HSH”), a Pennsylvania-incorporated provider of home healthcare services based in Philadelphia.
The total consideration is
HSH is an established, revenue-generating and profitable healthcare services business. For the year ended 31 December 2025, HSH reported gross receipts of approximately
The proposed acquisition represents the first in a planned programme of acquisitions of established, revenue-generating and profitable healthcare businesses over the coming year. This strategy is intended to complement Davion’s existing portfolio of proprietary healthcare technologies, broaden its commercial operations and build a more diversified healthcare group.
HSH provides skilled nursing, home health aide and rehabilitation services to patients in Philadelphia and surrounding areas. Its clinical programmes include wound care, lymphedema management, dementia and diabetes care, telehealth and rehabilitation. Its workforce includes registered nurses, licensed practical nurses, home health aides, physical and occupational therapists and social workers.
HSH provides care to patients of all ages, from children to the elderly, helping individuals remain in their own homes rather than requiring residential or institutional care. According to its website, HSH holds JCAHO accreditation and Medicare and Medicaid certifications, is fully insured and bonded, and accepts major insurance plans.
The acquisition would also extend Davion’s activities beyond the development and commercialisation of healthcare products into the delivery of care in patients’ homes. It could provide opportunities to evaluate the use of Davion’s non-invasive monitoring technologies in home healthcare, including wound monitoring and preventative care. Any integration or deployment plans will be developed following completion.
Glenn Williams, Chief Executive Officer of Davion, commented:
“HSH is an established and profitable business that will bring meaningful revenues and earnings to Davion, while giving us a direct presence in home healthcare and opportunities to introduce our monitoring and diagnostic technologies closer to patients. Importantly, this is the first in a planned programme of acquisitions of revenue-generating, profitable healthcare businesses over the coming year, as we look to build a broader and more diversified Group combining our proprietary technologies with established operating businesses. We look forward to working with HSH’s management to support its existing operations and explore opportunities to integrate our technologies into the delivery of care at home.”
Manilal Mathai, Co-owner and Chief Executive Officer of HSH, added:
“We share Davion’s commitment to improving care for patients outside hospital settings. Joining forces would give us an opportunity to combine HSH’s home healthcare experience with Davion’s technology-led approach, while continuing to focus on the quality and continuity of care we provide to patients and families.”
Media Enquiries
Rosewood Communications
+44 (0) 20 7653 8702
davion@rosewoodpr.co.uk
Investor Relations Inquiries
Mark Komonoski
Partner
Integrous Communications
Toll Free: 877-255-8483
Mobile: 403-470-8384
About Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.
The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare.
Davion’s growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio and commercial, manufacturing and distribution capabilities.
Further information is available at www.davionhealthcare.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions.
The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable law.
The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Davion Healthcare's acquisition of Healthcare Stat Homecare?
The total consideration is $13.5 million, comprising $8 million in cash and $5.5 million in Davion shares issued at an agreed value of $13 per share. The acquisition agreement is dated 27 October 2026.
When is Davion Healthcare expected to complete the Healthcare Stat Homecare acquisition?
Completion is expected on or before 31 December 2026, subject to the terms of the acquisition agreement.
How does Davion plan to integrate its technology with Healthcare Stat Homecare?
Integration or deployment plans will be developed following completion. Davion sees potential opportunities to evaluate its non-invasive monitoring technologies in home healthcare, including wound monitoring and preventative care; these are possibilities rather than agreed deployment plans.